Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Oct 12, 2010

Premium

Jaymie Sawyer has joined SQI Diagnostics in the newly created role of vice president of research and development.

Sawyer previously held various senior roles at BD Biosciences. Prior to that, Sawyer was associate director of R&D at Dyax, protein bioarrays team leader at Motorola Life Sciences Research, and antibody engineering group leader at Boehringer Mannheim Diagnostics.


Myconostica last week appointed David Evans as an independent non-executive director.

Evans is the former chief financial officer of Shield Diagnostics, now Axis-Shield. He is currently chairman or non-executive director of several companies, including Epistem, Immunodiagnostic Systems, and Omega Diagnostics.


David Mack has joined Pathwork Diagnostics' board of directors, the firm said last week. Mack is director of Alta Partners, a San Francisco-based venture capital firm that has invested in Pathwork.


Life Technologies has appointed Paul Billings as its new chief medical officer.

Billings recently served as director and chief scientific officer at the Genomic Medicine Institute at El Camino Hospital, and he currently is a member of the Secretary’s Advisory Committee on Genetics, Health, and Society in the US Department of Health and Human Services, where he helps analyze and make recommendations on genomic medicine policy.

After a career in academia, Billings was a founder or CEO of several companies, including GeneSage, Omicia, and Cellective Dx. He also served as vice president of corporate development at Laboratory Corporation of America.


NanoString Technologies has appointed Barney Saunders as chief commercial officer. Saunders previously was vice president and general manager at Agilent Technologies, where he led the company's gene expression business unit and worked in its life science investing activities. Before serving at Agilent, Saunders spent 13 years at Amersham Biosciences.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.